Published in CMAJ on August 01, 1986
Cough associated with captopril and enalapril. Br Med J (Clin Res Ed) (1987) 2.20
Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed) (1988) 1.29
New drugs for the treatment of hypertension: where do they fit? Can Fam Physician (1987) 0.75
Unusual Complication of ACE Inhibitor-Induced Cough. Can Fam Physician (1989) 0.75
Cough and wheeze caused by inhibitors of angiotensin-converting enzyme. N Engl J Med (1986) 2.65
Recommendations from the Canadian Hypertension Society Consensus Conference on the Pharmacologic Treatment of Hypertension. CMAJ (1989) 4.76
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther (1976) 3.16
Xylazine hydrochloridine (Rompun) overdose in man. Clin Toxicol (1979) 2.00
Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther (1974) 1.81
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol (1976) 1.71
Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol (1984) 1.66
Plasma digoxin concentrations in patients on admission to hospital. Br Heart J (1974) 1.46
Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay. Clin Chem (1983) 1.38
Duration of action of beta-blocking drugs. Br Med J (1973) 1.33
Variability in prescription drug utilization: issues for research. CMAJ (1996) 1.24
Quinidine-rifampin interaction. N Engl J Med (1981) 1.14
Measurement of partial agonist activity of pindolol. Clin Pharmacol Ther (1981) 1.13
Correlation of reduction of exercise heart rate with blood levels of atenolol after oral and intravenous administration. Postgrad Med J (1977) 1.13
Phenytoin-theophylline interaction. N Engl J Med (1982) 1.10
Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology (1988) 1.08
Cardiac dose-response relationships of oral and intravenous pindolol. Br J Clin Pharmacol (1982) 1.08
Relationships between heart rate and PR interval during physiological and pharmacological interventions. Br J Clin Pharmacol (1987) 1.03
An audit of requests for therapeutic drug monitoring of digoxin: problems and pitfalls. Ther Drug Monit (1983) 1.03
Grapefruit juice--felodipine interaction in the elderly. Clin Pharmacol Ther (2000) 1.01
Evaluation and application of the linear variable differential transformer technique for the assessment of human dorsal hand vein alpha-receptor activity. Clin Pharmacol Ther (1985) 1.00
Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther (1978) 0.99
Tolerance and cardiovascular effects of single dose felodipine/beta-blocker combinations in healthy subjects. J Cardiovasc Pharmacol (1987) 0.97
A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc) in hypertension. Betaloc Compliance Canadian Cooperative Study Group. Clin Invest Med (1984) 0.97
Impaired enzyme induction by rifampicin in the elderly. Br J Clin Pharmacol (1984) 0.95
A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke (1985) 0.93
Increased venous alpha-adrenoceptor responsiveness in patients with reflex sympathetic dystrophy. Ann Intern Med (1993) 0.93
Cyclosporin-erythromycin interaction in normal subjects. Br J Clin Pharmacol (1987) 0.92
Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma. Clin Pharmacol Ther (1986) 0.91
Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation (1982) 0.91
Mean apical concentration and duration in the comparative bioavailability of slowly absorbed and eliminated drug preparations. J Pharm Sci (1988) 0.89
The influence of age on dorsal hand vein responsiveness to norepinephrine. Clin Pharmacol Ther (1986) 0.87
Digoxin therapy during T-tube biliary drainage in man. JAMA (1978) 0.86
Relation of amiodarone hepatic and pulmonary toxicity to serum drug concentrations and superoxide dismutase activity. Am J Cardiol (1990) 0.86
Simplified liquid-chromatographic assay of amiodarone and desethylamiodarone after solid-phase extraction. Clin Chem (1986) 0.86
Creatinine elevation in patients receiving amiodarone correlates with serum amiodarone concentration. Br J Clin Pharmacol (1993) 0.85
Correlation of amiodarone dosage, heart rate, QT interval and corneal microdeposits with serum amiodarone and desethylamiodarone concentrations. Am J Cardiol (1989) 0.83
Familial studies of heritability of alpha1-adrenergic receptor responsiveness in superficial veins. Clin Pharmacol Ther (1997) 0.82
Cholestyramine and spironolactone and their combination in digitoxin elimination. Clin Pharmacol Ther (1980) 0.82
Genetic aspects of variability in superficial vein responsiveness to norepinephrine. Clin Pharmacol Ther (1991) 0.82
Ineffectiveness of beta-adrenergic blockers on ventilatory response to carbon dioxide. Clin Pharmacol Ther (1982) 0.81
Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study. Hypertension (1994) 0.77
A double-blind, randomized trial of PY108-068 in acute ischemic cerebral infarction. Stroke (1989) 0.77
Plasma and tissue digoxin concentrations in patients undergoing cardiopulmonary bypass. Br Heart J (1975) 0.76
Quinidine interaction with nifedipine and felodipine: pharmacokinetic and pharmacodynamic evaluation. Clin Pharmacol Ther (1993) 0.76
Influence of cardioselectivity and respiratory disease on pulmonary responsiveness to beta-blockade. Eur J Clin Pharmacol (1984) 0.76
The cyclosporin-erythromycin interaction: impaired first pass metabolism in the pig. Br J Pharmacol (1991) 0.75
The heart rate-PR interval relationship: a model for evaluating drug actions on SA and AV nodal function. Br J Clin Pharmacol (1990) 0.75
Contrasts between pindolol and propranolol concentration-response relationships. Br J Clin Pharmacol (1985) 0.75
Persistent tardive dyskinesia. Br Med J (1971) 0.75
Interaction between oral verapamil and beta-blockers during submaximal exercise: relevance of ancillary properties. Clin Pharmacol Ther (1991) 0.75
Eczema. J Natl Med Assoc (1910) 0.75
Gastric emptying before and after transverse gastroplasty for morbid obesity. Clin Nucl Med (1986) 0.75
Measurement of partial agonist activity in man and its therapeutic relevance. Arq Bras Cardiol (1984) 0.75
Pamatolol: phase I evaluation of the pharmacodynamics of a cardioselective beta adrenoceptor blocking drug. Clin Pharmacol Ther (1978) 0.75
Duration of drug action. Am Fam Physician (1980) 0.75
Kinetics of pamatolol, a cardioselective beta adrenoreceptor blocker. Clin Pharmacol Ther (1979) 0.75
Accelerated systemic hypertension after cardiac transplantation--possible vascular alpha-receptor hypersensitivity. Am J Cardiol (1984) 0.75
After Eastman: a boost for clinical research? Clin Invest Med (1986) 0.75
Coexisting medical problems: assessment and management for surgery. Int Anesthesiol Clin (1984) 0.75
Observations on three dosage forms of pindolol. Am Heart J (1982) 0.75
Biliary excretion and enterohepatic recirculation of practolol in man. Ir J Med Sci (1976) 0.75
Verapamil in chronic atrial fibrillation: variable patterns of response in ventricular rate. Clin Cardiol (1984) 0.75
Comparison of the electrophysiologic effects of intravenous and oral verapamil in patients with paroxysmal supraventricular tachycardia. Am J Cardiol (1982) 0.75
Elevation of serum total cholesterol and triglyceride levels during amiodarone therapy. Am J Cardiol (1988) 0.75
Evaluation of once daily endralazine in hypertension. Eur J Clin Pharmacol (1986) 0.75